Scisparc Ltd. current report, Q1 FY2021

SciSparc Ltd. Form 6-K Summary

Business Context and Reporting Period

This Form 6-K was filed by SciSparc Ltd., a foreign private issuer based in Ramat Gan, Israel, on February 10, 2021. The report covers the month of February 2021 and serves to disclose a material corporate development via a press release.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event rather than a financial statement.

Material Changes

On February 10, 2021, SciSparc Ltd. announced a strategic partnership with Procaps. The agreement covers the development and production of the company's CannAmide™ technology and its SCI-110 product candidate.

Guidance, Outlook, and Risks

The filing does not contain specific financial guidance, management commentary on future performance, or a detailed risk assessment beyond the context of the new partnership. The primary focus is the execution of the manufacturing and development agreement.

Key Facts for Investor Verification

  • SciSparc has engaged Procaps for the development and production of CannAmide™ and SCI-110.
  • The press release detailing this agreement is attached as Exhibit 99.1.
  • No financial results or updated guidance were included in this specific filing.